Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

Europrobe™ Gamma + Fluorescence · Dual Opto-Nuclear Probe — what the dual-modality literature says.

Six real anchor citations across the workflow the world-first dual gamma + ICG NIR fluorescence probe is bought for — combined-modality sentinel-node biopsy where one probe reads both channels at the actual dissection depth. Covers the foundational NIR + Tc-99m randomised breast trial (Van der Vorst 2012), the combined-modality gold-standard demonstration (Schaafsma 2013 · 48/48 vs blue-dye 42/48), the hybrid-tracer workflow choice (Vreeburg 2023 · nanocolloid vs nanoscan), a modern 476-patient breast comparison (Gâta 2025), the melanoma ICG-depth-ceiling meta-analysis that shows where a probe-based NIR channel becomes essential (Wölffer 2024), and the dual-probe architecture characterisation paper the SOE 3214 open + SOE 3214-AF laparoscopic geometries implement clinically (Brouwer 2014). Every DOI + journal reference verified; all open-access URLs where available.

48 / 48combined gamma + NIR vs blue-dye 42/48 SLN detection (Schaafsma 2013)
96 %SLN success in randomised NIR + Tc-99m breast trial (Van der Vorst 2012)
1 – 2 cmICG NIR depth ceiling — probe channel fills the gap (Wölffer 2024)
Product specsDetector-material family
Filter
Van der Vorst 2012 · NIR + Tc-99m ± blue dye
100 % NIR / 89 % Tc / 84 % blue
NIR + Tc-99m + blue dye
blue-dye contributes nothing on top
vs
100 % NIR / 100 % Tc
NIR + Tc-99m (no blue dye)
combined modality — blue dye eliminated from workflow
Foundational · Breast RCT2012
96 % · 24 pts100 % fluorescence-detection rate in both arms across 24 randomised breast-cancer patients; 96 % overall SLN success; no ICG-related adverse reactions. The foundational randomised trial that established NIR + Tc-99m as viable — and that blue dye adds nothing on top of the combined-modality workflow

Randomized comparison of near-infrared fluorescence imaging using indocyanine green and ⁹⁹ᵐTc with or without patent blue for the sentinel-lymph-node procedure in breast cancer patients

Annals of Surgical Oncology 19(13):4104 – 4111 (open access) — Van der Vorst, Schaafsma, Verbeek, Hutteman, Mieog, Lowik, Liefers, Frangioni, van de Velde, Vahrmeijer (LUMC)

Hybrid gamma + NIR vs blue dye — Schaafsma 2013
48 / 48 SLNs
Combined gamma + NIR (hybrid tracer)
100 % preoperative + intraoperative identification
vs
42 / 48 SLNs
Blue-dye alone
6 nodes missed vs the combined-modality reference
Combined-modality · 48/482013
48 / 48Combined gamma-probe + ICG-⁹⁹ᵐTc-nanocolloid hybrid tracer localised every axillary SLN (48 / 48) across 32 breast-cancer patients — while blue-dye alone missed 6 nodes (42 / 48). The combined-modality gold-standard demonstration that the dual opto-nuclear probe delivers in one instrument

Clinical trial of combined radio- and fluorescence-guided sentinel-lymph-node biopsy in breast cancer

British Journal of Surgery 100(8):1037 – 1044 (open access) — Schaafsma, Verbeek, Rietbergen, van der Hiel, van der Vorst, Liefers, Frangioni, van de Velde, van Leeuwen, Vahrmeijer

Hybrid-tracer fluorescence intensity — Vreeburg 2023
24 × 10⁹ A.U.
ICG-⁹⁹ᵐTc-nanocolloid
stronger fluorescence signal at the back-table read; ICG dispersed on the colloid
vs
4.6 × 10⁹ A.U.
ICG-⁹⁹ᵐTc-nanoscan
ICG stacking causes fluorescence quenching; equivalent gamma-detection, weaker NIR headroom
Hybrid-tracer choice2023
5.2 × differenceBoth hybrid tracers deliver 100 % gamma-detection + 97 – 98 % fluorescence visualisation. But back-table fluorescence intensity was 4.6 × 10⁹ A.U. (nanoscan) vs 24 × 10⁹ A.U. (nanocolloid; p = 0.0054) — ICG stacking + quenching on the nanoscan formulation. The dispensing workflow choice matters for the fluorescence-channel headroom

Comparison of two hybrid sentinel-node tracers — indocyanine green (ICG)-⁹⁹ᵐTc-nanocolloid vs ICG-⁹⁹ᵐTc-nanoscan from a nuclear-medicine and surgical perspective

European Journal of Nuclear Medicine and Molecular Imaging 50(8):2282 – 2291 (open access) — Vreeburg, Azargoshasb, van Willigen, Molenaar, van Oosterom, Buckle, Slof, Klop, Karakullukcu, Donswijk, van der Poel, van Leeuwen, Brouwer, Rietbergen

Modern breast SLNB · gamma vs ICG — Gâta 2025
3.23 SLNs
Tc-99m gamma probe (n = 286)
radiotracer localisation; the incumbent standard
vs
3.20 SLNs
ICG NIR fluorescence (n = 190)
visual green fluorescence; simpler dispensing workflow; sub-2-cm depth ceiling
Modern breast · 476 pts2025
p = 0.860476 breast-cancer SLNB patients — Tc-99m gamma-probe (n = 286) vs ICG NIR (n = 190). Comparable nodes excised (3.23 vs 3.20 · p = 0.860) + comparable positive-node capture. Modern context — either modality gives accurate axillary staging; the dual opto-nuclear probe delivers both in one instrument

From gamma rays to green light — comparative efficacy of indocyanine green and technetium-99m in sentinel-lymph-node biopsy for breast cancer

Medical Sciences (Basel) 13(4):231 (open access) — Gâta, Ilieș, Antone, Pintican, Nistor-Ciurba, Țîțu, Orădan, Muntean, Filip, Irimie, Achimaș-Cadariu

ICG NIR depth-of-detection — Wölffer 2024
1 – 2 cm
tissue-penetration ceiling for surface NIR imaging
13 %
melanoma meta-FNR · ICG (Tc-99m 10 %)
Probe
reads NIR at the probe tip inside the wound
ICG NIR is non-inferior to Tc-99m once the surgical site is exposed — but the physics ceiling on tissue-through-fat penetration is real. The dual-channel probe fixes that boundary by reading NIR fluorescence at the probe tip, inside the wound, at the actual dissection depth.
Melanoma · depth ceiling2024
1 – 2 cmICG NIR penetration ceiling reported at 1 – 2 cm across the meta-analysis. Meta-FNR 13 % ICG vs 10 % Tc-99m — non-inferior once tissue depth is within reach. The reason a probe-based NIR channel that reads at the probe tip matters more than a surface NIR camera at the deep dissection plane

Sentinel-lymph-node detection in cutaneous melanoma using indocyanine-green-based near-infrared fluorescence imaging — a systematic review and meta-analysis

Cancers (Basel) 16(14):2523 (open access) — Wölffer, Liechti, Constantinescu, Lese, Zubler

Dual opto-nuclear probe architecture — Brouwer 2014
One probe
combined γ + NIR detection in a single body
Foot switch
modality control without an assistant
H&N SLN
validated workflow · extends to breast + gynae
The dual opto-nuclear probe concept — same probe reads both channels — is the answer to the practical OR problem of running gamma + NIR from two separate instruments. Every dispensing swap is a workflow risk; a single-probe dual-channel architecture eliminates it.
Dual-probe characterisation2014
Dual channelFoundational dual-probe characterisation — combined gamma + fluorescence single-probe geometry for sentinel-node biopsy in head-and-neck cancer. Same detector body reads both channels; foot-switch modality control; the mechanical + electronic architecture the SOE 3214 open + SOE 3214-AF laparoscopic Europrobe dual probes implement clinically

A hybrid radioactive and fluorescent tracer for sentinel-node biopsy in head and neck cancer — a novel intraoperative technique

European Journal of Nuclear Medicine and Molecular Imaging — Brouwer, van den Berg, Mathéron, van der Poel, van Rhijn, Bex, van Tinteren, Valdés Olmos, van Leeuwen, Nieweg

Back to Europrobe Gamma + Fluorescence product page

Standards, Regulator + Adjacent-Indication Reading

NEMA + EANM/SNMMI + AERB + CDSCO reference frameworks + adjacent-indication trials (GROINSS-V vulva, SENTI-ENDO endometrium) the laparoscopic dual-probe fits.

FILE

NEMA NU3-2004 — Performance Measurements for Non-Imaging Intraoperative Gamma Probes

International acceptance standard governing intraoperative-gamma-probe characterisation — sensitivity, spatial resolution, angular response, energy resolution, shielding. Applies to the gamma channel of the dual opto-nuclear probe.

Reference · NEMADownload
FILE

EANM / SNMMI — Practice Guidelines for Radionuclide-Guided Sentinel Node Biopsy

European (EANM) + North American (SNMMI) joint practice framework for radionuclide-guided sentinel-lymph-node biopsy — the standards environment the hybrid gamma + fluorescence workflow operates inside.

Reference · EANM / SNMMIDownload
FILE

AERB Safety Code for Nuclear Medicine Facility (India)

Indian regulatory framework for the Tc-99m leg of the hybrid workflow — pre-operative injection authorisation, transport, theatre handling, specimen-disposal chain.

Reference · AERBDownload
FILE

CDSCO — Indocyanine Green (ICG)

Central Drugs Standard Control Organisation reference for ICG as an operative fluorescence agent in India — the drug-regulatory leg the fluorescence channel operates under, alongside the AERB radionuclide leg.

Reference · CDSCODownload
FILE

GROINSS-V (Van der Zee 2008 · JCO) — SLN in vulvar cancer

Adjacent-indication reference — sentinel-node procedure as standard of care in selected early-stage vulvar cancer. The laparoscopic dual probe (SOE 3214-AF) is the practical answer for the trans-trocar workflow.

Reference · JCODownload
FILE

SENTI-ENDO (Ballester 2011 · Lancet Oncol) — SLN in endometrial cancer

Adjacent-indication reference — 88 – 97 % SLN detection rate in early-stage endometrial cancer. Laparoscopic dual-probe workflow fits.

Reference · Lancet OncolDownload

Surgical-Technique Videos

Educational demonstrations of the SLN workflow the dual opto-nuclear probe plugs into.

Europrobe™ Gamma + Fluorescence

More for this product

Each card opens a focused post for a specific specialty — clinical workflow and evidence, written for the persona you select.

For Surgical Oncologist

Surgical Oncologist

Hybrid tracer + six-step OR workflow

From hybrid ICG-99mTc-nanocolloid dispensing in NM to ex-vivo dual-modality confirmation. Foot-switch modality control; gamma sweep first, fluorescence toggle at the dissection plane.

Read this

Literature Radar · auto-updated daily

Latest radioguided + fluorescence-guided surgery research

Fresh peer-reviewed papers on hybrid gamma + fluorescence sentinel-node biopsy, ICG NIR imaging + fluorescence-guided surgery, dual-modality workflow and laparoscopic dual-probe workflows across the primary oncological indications. Auto-updated from Europe PMC.

See all in radar →
Loading recent papers…
Get the weekly digest →